Treatment of melanoma with alpha thymosin peptides in...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/17 (2006.01) A61K 31/166 (2006.01) A61K 31/337 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2708168

Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and an antineoplastic heat shock apoptosis activator (HSAA) such as STA-4783 (and optionally an antineoplastic cytotoxic chemotherapeutic agent such as paclitaxel), and/or optionally one or more additional anti-melanoma agents.

L'invention concerne le traitement d'un mélanome ou d'une métastase de ce dernier chez un patient humain dans une polythérapie qui inclut l'administration d'une combinaison de traitement de mélanome à un patient humain atteint de mélanome pendant un régime de traitement, la combinaison incluant un peptide d'alpha thymosine et un activateur d'apoptose de choc thermique antinéoplasique (HSAA) tel que STA-4783 (et facultativement un agent chimiothérapeutique cytotoxique antinéoplasique tel que le paclitaxel), et/ou facultativement un ou plusieurs agents anti-mélanome supplémentaires.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Treatment of melanoma with alpha thymosin peptides in... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of melanoma with alpha thymosin peptides in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of melanoma with alpha thymosin peptides in... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1503668

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.